baber/WOPTO huggingface dataset:
Patent NZ-265547-A (NZ)
Title: 10,11-methano-dibenzo-suberane derivatives, preparation and pharmaceutical compositions thereof
Inventor: PFISTER JURG ROLAND
IPC: C07D215/20
Filed: 1994-04-13
Abstract: 10,11-Methanodibenzosuberane derivatives, i.e., the compounds of Formula I: <CHEM>  wherein:   A is -CH2-CH2-, -CH2-CHR<a>-CH2-, where R<a> is H, OH or lower acyloxy of the formula -O-C(=O)-R', wherein R' is a cyclic, branched or straight chain monovalent alkyl radical of 1-6 carbon atoms, or -CH2-CHR<a>-CHR<b>-CH2-, where one of R<a> or R<b> is H, OH, or lower acyloxy of the formula -O-C(=O)-R', wherein R' is a cyclic, branched or straight chain monovalent alkyl radical of 1-6 carbon atoms, and the other is H;   R<1> is H, F, Cl or Br;   R<2> is H, F, Cl or Br; and R<3> is heteroaryl excluding heteroaryl with 2 condensed rings and 1 to 3 heteroatoms selected from the group consisting of N, O and S; or phenyl optionally substituted with F, Cl, Br, CF3, CN, NO2 or OCHF2; and the pharmaceutically acceptable salts thereof, are useful chemosensitizing agents, e.g., for cancer chemotherapy, particularly for treating multidrug resistance.
Patent NZ-266301-A (NZ)
Title: Anthra [1,9-cd]pyrazol-6(2h)-one derivatives;preparation of losoxantrone derivatives
Inventor: ZHANG LIN-HUA
IPC: C07D231/54
Filed: 1994-04-29
Abstract: This invention relates to compounds, including 5-chloro-2-[2-[[(4-methylphenyl)sulfonyl]oxy]ethyl]-7-[2,4,6-trimethylphenyl)methoxy]anthra[1,9-cd]pyrazol-6(2H)-one and analogs thereof, which are useful as intermediates for the synthesis of anthrapyrazolone anticancer agents, including losoxantrone. This invention also relates to methods for the synthesis of anthrapyrazolone anticancer agents, including losoxantrone.
Patent NZ-273139-A (NZ)
Title: Polyester whiteners comprising blue and red anthraquinones and anthrapyridones incorporated in the polyester polymer structure
Inventor: WEAVER MAX ALLEN
IPC: C08L67/00
Filed: 1994-08-17
Abstract: This invention provides certain blue substituted 1,4-bis(2,6-dialkylanilino) anthraquinones in combination with selected red anthraquinone and anthrapyridone (3H-dibenz[f,ij] isoquinoline-2,7-dione) compounds which provide a toner system useful in imparting a desirable neutral to slightly blue hue to polyesters having a yellow appearance. The thermally stable colored compounds can have polyester reactive groups and are preferably incorporated into the polyester polymer structure during polymerization.
Patent NZ-281230-A (NZ)
Title: Antitussue composition containing benzydamine used in conjunction with a centrally acting antitissue
Inventor: GALLI ANGELI DEPALMO
IPC: A61K31/435
Filed: 1995-02-22
Abstract: PCT No. PCT/EP95/00658 Sec. 371 Date Dec. 24, 1996 Sec. 102(e) Date Dec. 24, 1996 PCT Filed Feb. 22, 1995 PCT Pub. No. WO95/23602 PCT Pub. Date Sep. 8, 1995Oral antitussive pharmaceutical composition which allows a significant contact of its components with mucous membranes of the buccal cavity and comprises a centrally acting antitussive or a pharmaceutically acceptable salt thereof and benzydamine or a pharmaceutically acceptable acid addition salt thereof.
Patent NZ-299241-A (NZ)
Title: Systemic delivery of parathyroid hormone by oral inhalation
Inventor: PATTON JOHN S
IPC: A61K38/29
Filed: 1996-08-27
Abstract: The specification describes the pulsatile systemic delivery of parathyroid hormone and its use in the treatment of osteoporosis.  The preferred PTH concentration range is from 1mg/ml to 20mg/ml.
Patent NZ-323389-A (NZ)
Title: Salts of quinoline derivatives as NK3 antagonists
Inventor: GIARDINA GIUSEPPE ARNALDO MARI
IPC: A61P43/00
Filed: 1996-11-22
Abstract: A compound of formula (I) or a solvate thereof, characterised in that salt comprises a compound of formula (I) in anionic form and a salting cation; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine where: X is O, S, or N-C=N R, R1, R2, R3, R4 and R5 are disclosed in the specification. Also claimed is the use of the compound for treating primary, secondary or further disorders.
Patent NZ-331549-A (NZ)
Title: Compounds useful in treating sexual dysfunction
Inventor: GRANGER RICHARD H
IPC: A61K31/4523
Filed: 1997-01-28
Abstract: A use in the manufacture of a medicament for the treatment of sexual dysfunction of a compound of the following general formula (I) wherein, R1 is selected from N and CH, m is 0 or 1, R2 is selected from (CR8)2)n-m and (Cn-mR8)2(n-m)2' in which n is 4, 5, 6, or 7, the R8's in any single compound being the same or different, each R8 being selected from H and C1-C6 alkyl, or one R8 being combined with either R3 or R7 to form a single bond linking the no. 3' ring vertex to either the no. 2 or the no. 6 ring vertices or a single divalent linking moiety linking the no. 3' ring vertex to either the no. 2 or the no. 6 ring vertices, the linking moiety being a member selected from the group consisting of CH2, CH2-CH2, CH=CH, O, NH, N(C1-C6 alkyl), N=CH, N=C(C1-C6 alkyl), C(O), O-C(O), C(O)-O, CH(OH), NH-C(O), and N(C1-C6 alkyl)-C(O),  R3, when not combined with R8, is selected from H, C1-C6 alkyl, and C1-C6 alkoxy, R4 is either combined with R5 or is selected from H, OH, and C1-C6 alkoxy, R5 is either combined with R4 or is selected from H, OH, C1-C6 alkoxy, amino, mono(C1-C6 alkyl)amino, di(C1-C6 alkyl)amino, and CH2OR9, in which R9 is selected from H, C1-C6 alkyl, an aromatic carbocyclic moiety, an aromatic heterocyclic moiety, an aromatic carbocyclic alkyl moiety, an aromatic heterocyclic alkyl moiety, and any such moiety substituted with one or more members selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, hydroxy, halo, amino, alkylamino, dialkylamino, and methylenedioxy, R6 is H or CH2OR9, R4 and R5 when combined form a member selected from the group consisting of (II), (III), (IV) and (V) in which, R10 is selected from O, NH and N(C1-C6 alkyl), R11 is selected from O, NH and N(C1-C6 alkyl), R12 is selected from H and C1-C6 alkyl, and when two or more R12's are present in a single compound, such R12's are the same or different, p is 1, 2, or 3,  q is 1 or 2 and R7, when not combined with any R8, is selected from H, C1-C6 alkyl and C1-C6 alkoxy. These compounds enhance the stimulation of a-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptors.
Patent NZ-335209-A (NZ)
Title: Process for converting hydroxy heteroaromatics to arylamines
Inventor: PEET NOTON P
IPC: C07D215/38
Filed: 1997-09-12
Abstract: A process of converting a nitrogen-containing hydroxy heteroaromatic compound to an a heteroaromatic arylamine, comprises the steps of : 1) treat a salt of a nitrogen-containing hydroxy heteroaromatic compound with an alkylating agent; and 2) treat the reaction mixture with a Smiles solvent system and raising the temperature of the reaction mixture.  A compound made according to the above process is also disclosed.
Patent NZ-337198-A (NZ)
Title: Assembly of replacement wear parts on a plough body
Inventor: SKJAEVELAND MAGNE
IPC: A01B15/06
Filed: 1998-02-04
Abstract: combination of a soil-working part (21) and a mounting part (24) to be provided on a plough body (10) is claimed.  Working part (21) has a pair of opposed working tips (22, 23) intended to be mounted on said mounting part (24) so that one of tips (22) is an outboard tip which projects from the mounting part (24) so as to be capable of carrying out a soil-working operation in use of the plough body (10).  The other of tips (23) is an inboard tip in which the working part (21) has first and second modes of adjustment relative to the mounting part (24) when tip wear occurs.
Patent NZ-337520-A (NZ)
Title: biological culture of L. rhamnosus and compositions useful in immunity enhancement
Inventor: GILL HARSHARNJIT S
IPC: A23L27/60
Filed: 1998-08-18
Abstract: biologically pure culture of either L.rhamnosus HN001 AGAL deposit number NM97/09514 dated 18 August 1997, or L. rhamnosus Hno67 AGAL deposit number NM97/01925 dated 11 February 1998, and a composition comprising either of these strains in a cultured food like milk, yoghurt, cheese, milk powder, and a method of enhancing natural and acquired immunity by administering the above composition.
Patent NZ-337523-A (NZ)
Title: An apparatus for separating and particulating egg membranes and egg shells
Inventor: MACNEIL JOSEPH H
IPC: B03D1/00
Filed: 1998-03-18
Abstract: An apparatus (100) for separating a membrane attached to egg shells comprising: a) a reducing device (104) for abrading the membrane from the egg shells constructed and arranged to output the egg shells (114) and the abraded membranes(118) in particulate form; b) a tank (102) containing a liquid for receiving the abraded membranes and egg shell particles; c) an agitator constructed and arranged to displace the clean egg shell particles (120) settled on a bottom of the tank so that the abraded membranes (118) trapped beneath the egg shells particles are released and entrained in the liquid; d) a membrane recovery device (106) communicating with the tank and e) a clean egg shell particle recovery device (108) communicating with the tank.
Patent NZ-503293-A (NZ)
Title: Liposomal camptothecin formulations also comprising at least one phospholipid
Inventor: MOYNIHAN KAREN LEWIS
IPC: A61K9/127
Filed: 1998-09-15
Abstract: A liposome comprises at least one phospholipid and 7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin. The liposome may further comprise cholesterol. The liposome can encapsulate camptothecin wherein the liposome is comprised of hydrogenated soy phosphatidylcholine (HSPC) and cholesterol. The HSPC:cholesterol are in a molar ratio of about 2:1 and the lipid:camptothecin molar ratio is from 10:1 to 40:1. The liposome is unilamellar with an average size of less than 100nm The liposome can be produced by forming a lipid film or powder comprised of phosphatidylcholine and cholesterol, hydrating the lipid film or powder with an aqueous buffer containing a counterion solution. Applying a shearing force to obtain liposomes that are unilamellar and less than 100nm. Then 7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin is added to the aqueous medium. A gradient is generated between the aqueous medium inside the liposome and the aqueous medium external to the liposome whereby the gradient causes the 7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin to load into the liposome. The gradient may be a pH gradient. Further a membrane permeable amine may be added to the aqueous medium external to the liposome whereby the pH of the aqueous inside the liposome is decreased. The liposomes may be used in a pharmaceutical composition for inhibiting the growth of a tumor.
Patent NZ-511993-A (NZ)
Title: Hydroxy diphenyl urea sulfonamides useful as IL-8 receptor antagonists
Inventor: JIN QI
IPC: A61K31/4465
Filed: 1999-12-15
Abstract: A hydroxy diphenyl urea sulphonamide derivative or a pharmaceutically acceptable salt thereof has the formula (I) wherein: each Rb is independently hydrogen, NR6NR7, OH, ORa, or optionally substituted alkyl, aryl, arylalkyl, arylalkenyl; cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterorarylalkenyl, heterocyclic, heterocyclic-alkyl, or a heterocyclic-alkenyl or the two Rb substituents join to form either an optionally unsaturated 3-10 membered cycloalkyl ring or a 3-10 membered heterocyclic ring containing, independently, 1 to 3 NRa, O, S, SO, or SO2 moieties; each R1 is independently hydrogen, halogen, nitro, cyano, alkyl, haloalkyl, alkenyl, alkoxy, haloalkoxy, azide, S(O)tR4, (CR8R8)qS(O)tR4, hydroxy, hydroxyalkyl, aryl, arylalkyl, arylalkenyl, aryloxy, arylalkyloxy, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroaryl alkyloxy, heterocyclic, heterocyclic-alkyl, heterocyclic-alkyloxy, heterocyclic-alkenyl, (CR8R8)qNR4R5, (CR8R8)qC(O)NR4R5, alkenyl-C(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alkenylC(O)R11, alkenylC(O)OR11, (CR8R8)qC(O)OR11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qC(NR4)NR4R5, (CR8R8)qNR4C(NR5)R11, (CR8R8)qNHS(O)tR13, (CR8R8)qS(O)tNR4R5, or two R1 moieties together may form O-(CH2)sO or a 5 to 6 membered optionally saturated ring, and wherein the alkyl, aryl, arylalkyl, heteroaryl, heterocyclic moieties may be optionally substituted; Y is hydrogen, halogen, nitro, cyano, haloalkylalkyl, alkenyl, alkoxy, haloalkoxy, azide, (CR8R8)qS(O)tRa, (CR8R8)qORa, hydroxy, hydroxyalkyl, aryl, arylalkyl, arylalkenyl, aryloxy, arylalkyloxy, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroaryl alkyloxy, heterocyclic, heterocyclic-alkyl, heterocyclic-alkyloxy, heterocyclic-alkenyl, (CR8R8)qNR4R5, alkenyl-C(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alkenylC(O)R11, (CR8R8)qC(O)OR11, alkenylC(O)OR11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qNHS(O)tR13, (CR8R8)qS(O)tNR4R5, (CR8R8)qC(NR4)R5, (CR8R8)qNR4C(NR5)R11, or two Y moieties together may form O- (CH2)s-O or a 5 to 6 membered optionally saturated ring, and wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic, heterocyclicalkyl groups may be optionally substituted; Ra, R4 to R8 are as defined in the specification; m is 1 to 3; n is 1 to 3; q is 0 to 10; t is 0 to 2 and s 1 to 3. The compounds are useful in treating a chemokine mediated disease, wherein the chemokine binds to an IL-8 a or b receptor.
Patent NZ-526538-A (NZ)
Title: Anti-endoparasitic amidoacetonitrils
Inventor: DUCRAY PIERRE
IPC: A61K31/44
Filed: 2001-12-18
Abstract: Disclosed are compositions and methods for controlling helminths in warm-blooded animals, comprising compounds of formula I, wherein: R1 is substituted alkylene, R2 is optionally substituted phenyl or pyridyl, R3 is methyl, R4 is H, alkyl or halo-alkyl, R8 and R9 are H, A is CR6R7, CH=CH or Ca"C, m and n are independently 0 or 1.
Patent NZ-527693-A (NZ)
Title: Water-soluble triazole fungicide
Inventor: MORI MAKOTO
IPC: C07D417/06
Filed: 2002-02-20
Abstract: Triazole compounds of formula (I) and its pharmacologically acceptable salts that are soluble in water and have antifungal activity are disclosed, wherein: X represents such a group that the compound represented by the formula X-OH has antifungal activity or X is as defined in the specification; L represents -(C6-10 aryl)CH2- in which the aryl has substituents on neighboring carbon atoms, or L is as defined in the specification; and R represents -P(=O)(OH)2, or R is as defined in the specification.
Patent NZ-527781-A (NZ)
Title: Crystalline rapamycin
Inventor: NAVARRO FRANCOIS
IPC: A61K/
Filed: 2003-08-25
Abstract: 40-O-(2-hydroxy-ethyl)-rapamycin in crystalline non-solvate form. Pharmaceutical compositions comprising the abovementioned compound and processes for its manufacture are also disclosed. (62) Divided out of 511936
Patent NZ-529632-A (NZ)
Title: Non-aqueous release from paper machine equipment
Inventor: PEASE JACQUELINE K
IPC: C08F10/10
Filed: 2002-05-23
Abstract: Disclosed is a method of improving the release of paper webs from the surface of press rolls or other paper making or converting equipment by applying to such a surface non-aqueous, non-curing hydrocarbon polymer compositions. The non-curing hydrocarbon polymers have the formula (CH3)3C-[-C(R1)(R2)-C(R3)(R4)-]n-C(R5)=C(CH3)2 (I) wherein R1 through R5 are hydrogen or -CH3, with at least one of R1 through R4 being -CH3, and n is such that the number average molecular weight of such hydrocarbon polymers is from 50 to 3000. They may be hydrogenated. Preferred non-curing hydrocarbon polymers are polybutenes of the formula (CH3)3C-[-CH2-C(CH3)2-]n-CH=C(CH3)2 (II). Preferred compositions comprise at least one such hydrocarbon polymer component having a number average molecular weight from 400 to 700 and a second such component having a number average molecular weight of 100 to 400. The compositions are applied to the equipment surface in the absence of water.
Patent NZ-532572-A (NZ)
Title: Audio signal processing for generating apparent bass through harmonics
Inventor: BEYER ROBERT PATRICK
IPC: H04S5/02
Filed: 2004-04-26
Abstract: Audio signal processing apparatus and methods for reproducing bass frequencies through speakers are disclosed. A peak-hold generator is used to generate harmonics of a low frequency signal by shaping the waveform of the signal with respect to time. A psychoacoustic phenomenon means that the harmonics lead a listener to perceive the low frequency signal even though the fundamental is not present. This allows low frequency audio to be conveyed through hardware that is not capable of reproducing the actual frequency.
Patent NZ-540521-A (NZ)
Title: Variable flow water dispenser for refrigerator freezers
Inventor: HORTIN GREGORY G
IPC: F25C5/00
Filed: 2005-06-02
Abstract: A water dispenser for a refrigerator having first and second valves 43, 46 of different flow rates, allowing a variable water flow rate to be delivered, is disclosed. The dispenser is mounted in the refrigerator door and has a dispensing nozzle and a user-adjustable flow control. A user can select a desired flow rate and an actuator will operate either or both of the first and second valves to deliver water at the selected rate. An ice and water dispenser is also disclosed, where the user may adjust the flow rate of delivered water and also selectively deliver water to the ice maker.
Patent NZ-547239-A (NZ)
Title: Safety line anchor
Inventor: POLDMAA ARVO
IPC: E04G21/32
Filed: 2004-10-14
Abstract: A safety line anchor (10) is disclosed which includes mounting means (2) for fixing the anchor to a structure, deformation means (3) for plastically deforming on application of a high load arid receiving means (12) for receiving a safety line, The deformation means is interposed between the mounting and the receiving means and is adapted to at least partially absorb some of the energy associated with the application of the high load by deforming progressively as the load is applied.
Patent NZ-547775-A (NZ)
Title: Floorboard, system and method for forming a flooring, and a flooring formed thereof
Inventor: PERVAN DARKO
IPC: E04F15/04
Filed: 2004-12-02
Abstract: A system for forming a flooring is disclosed. The system comprises rectangular floorboards (1, 1') including first and second types of floorboards (A, B), on which first and second locking means are arranged in pairs on opposing short edges (5a, 5b) and long edges (4a, 4b), respectively, and on which the locking means of the first type of floorboard (A) along one pair of opposing joint edges is mirror inverted relative to the corresponding locking means along the same pair of opposing joint edges of the second type of floorboard (B). The system comprises a third of floorboard (C), which is so designed that a first one (5b) of its two short edges presents the first locking means (12) and both its long edges (4a, 4b) and its other short edge (5a) presents the second locking means. Floorboards, a flooring and a method for forming the flooring are also disclosed.
Patent NZ-548592-A (NZ)
Title: Elevator cabin door
Inventor: HOERLER MARCO
IPC: B66B13/30
Filed: 2005-01-21
Abstract: An elevator cabin door that folds around a vertical axis during its closing movement is disclosed. The door is subject to a continuous tension exercised by a energy accumulator, preferably a spring, in order to keep the door opened, while, on the other door side, a traction action in opposite direction is exercised by means of two traction means (6, 7) that always pull the door and that wind around a second motorised vertical axis (8). The cabin door can then be mechanically coupled with a landing entrance door (11) so that the cabin door opening provokes the landing entrance door opening by means of dragging. The necessary torque on the different vertical axes of the construction are preferably exercised by cylindrical or helicoidal coil spring acting directly on the axes.
Patent NZ-549479-A (NZ)
Title: Tamper resistant dosage form comprising an adsorbent and an adverse agent
Inventor: ABREU OSVALDO
IPC: A61K9/20
Filed: 2005-03-23
Abstract: Disclosed is a dosage form comprising an active agent, an adsorbent, and an adverse agent, wherein at least a majority of the adverse agent is adsorbed onto the adsorbent, and wherein the adverse agent is an antagonist of the active agent or wherein the adverse agent causes vomiting, nausea, or diarrhoea, when absorbed into an animal's or patient's bloodstream. Also disclosed is an oral dosage form comprising a plurality of first particles comprising an opioid agonist and a plurality of second particles comprising an adsorbent and an opioid antagonist, wherein at least a majority of the opioid antagonist is adsorbed onto the adsorbent and wherein the first particles provide a controlled release of the opioid agonist upon oral administration to a patient. Also disclosed is a method for preparing a dosage form, comprising:providing an adsorbent;providing a liquid comprising an adverse agent; contacting the adsorbent with the liquid comprising the adverse agent for sufficient time to allow at least a portion of the adverse agent to adsorb onto the adsorbent;separating the adsorbent from the liquid phase; and optionally, washing the adsorbent, or comprising providing an adsorbent; providing a liquid comprising an adverse agent; adding the adsorbent to a fluidized bed; fluidizing the adsorbent; spraying the liquid onto the fluidized adsorbent; and optionally, drying the adsorbent.
Patent NZ-551014-A (NZ)
Title: Spark electrode assembly
Inventor: BURTON ROBERT L
IPC: H01T13/14
Filed: 2005-05-25
Abstract: A spark electrode assembly (10) for igniting a combustible gas to lubricate a glassware mold surface (21) has an electrode (78) and an inner insulator (24) surrounding at least in part the electrode for mounting the electrode to a support structure (14) with an end (80) of the electrode being disposed relative to one side of the support structure for attachment to a source of electrical power and another end (90) of the electrode being positioned adjacent to a ground element (94) across a spark gap(96). An outer insulator (54) surrounds at least in part and is spaced from the inner insulator adjacent to the another end of the electrode to inhibit electrical leakage from the electrode to the support structure by providing an open space (76) between the inner and outer insulators, and the inner insulator has an outer surface with an enlarged mid-section (34) extending radially outwardly from the outer surface. The mid-section has upper and lower portions (38, 40) axially spaced from one another to define at least in part an air passage (46) in the inner insulator.
Patent NZ-551258-A (NZ)
Title: A biomolecule-containing formulation of increased stability
Inventor: JUNNARKAR GUNJAN
IPC: A61K31/7024
Filed: 2005-05-23
Abstract: Provided is a suspension formulation that is deliverable via an implantable delivery device comprising: a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics; and a dry particle formulation comprising a biomolecule dispersed in the vehicle; characterized in that a first surfactant is incorporated in the vehicle and a second surfactant is incorporated in the dry particle formulation. Further provided are methods of enhancing release of biomolecules, including interferon, in a hydrophilic release rate using the formulation.
Patent NZ-554142-A (NZ)
Title: Antibody production method comprising inserting antigen releasing device into mammal so antibodies are released into its milk
Inventor: TAY KWANG GUAN
IPC: A61K39/104
Filed: 2005-10-06
Abstract: Disclosed is a method for inducing the sustained release of antibodies in the milk of a nonhuman mammal comprising the step of: a) administering a primer composition; b) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary Iymph node; and c) administering a booster composition comprising antigen to a mammal after the antigen releasing device has been implanted, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary Iymph node which stimulates antibody secretion into a mammary gland.